Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Pain
- Therapeutic
- Pharmaceuticals
- Disease
- Delivery
- Osteoarthritis
- Arthritis
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1508
License Grant
The Company has licensed the exclusive right to market Oruvail® outside of the United States.
License Property
Oruvail®/Oscorel® is a controlled release formulation of ketoprofen indicated for treatment of the symptoms of inflammation and pain associated with rheumatoid arthritis and osteoarthritis.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 66786
License Grant
The company transferred to the Licensee, a Swedish corporation, the Investigational New Drug (IND) and New Drug Applications (NDA) for the product. The Licensee is responsible for the commercialization of VIMOVO. The Licensee will have rights to commercialize VIMOVO outside of the United States.
License Property
VIMOVO is the brand name for a proprietary fixed-dose combination of enteric-coated naproxen, a pain-relieving NSAID and immediate-release esomeprazole magnesium, a PPI, in a single delayed-release tablet and is a product in our PPI-NSAID (“PNâ€) platform. It is for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers
Field of Use
This agreement pertains to the drug industry relating to the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Also to decrease the risk of gastric ulcers.
IPSCIO Record ID: 178742
License Grant
The Austrailian Licensor licensed the Technology to the Licensee for a period commensurate with the term of this Agreement, to use and take advantage of the Technology for the purposes of completing the development of the Product and manufacturing and selling the Product within the Territory during the term of this Agreement.
License Property
The Austrailian Licensor is the proprietor of the Technology in relation to the manufacture and production of the nonsteroidal anti-inflammatory drug.
Product A once daily ketoprofen product that will be the rated A/B substitutable for Oruvail 200 by the United States Food and Drug Administration.
Ketoprofen is generally prescribed for arthritis-related inflammatory pains or severe toothaches that result in the inflammation of the gums.
Field of Use
The Licensee has expertise in capsule and tablet technology and in the packaging, promotion and distribution of pharmaceutical products, wishes to obtain the right to import, distribute, promote and sell the Product within the Territory.
IPSCIO Record ID: 5599
License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.
IPSCIO Record ID: 4380
License Grant
The Australian Licensor grants to the Licensee a sole and exclusive, world-wide, royalty-bearing right and License under the IP to develop, make, have made, use, sell, offer to sell and import Licensed Products. The Licensor retains all other rights to the IP.
License Property
The Licensee may grant Sublicenses.
The Licensed Technology relates to methods and apparatus for producing APIs having an average particle size of 1,000 nanometers or less, including nano-milling methods and apparatus and pharmacoactive compositions of matter having an particle size of 1,000 nanometers or less and methods for their use.
The reformulation efforts as to Indocin®/Indocid® and the Initial Selected Compounds shall be performed in accordance with the milestones specified.
Indocin is a nonsteroidal anti-inflammatory drug (NSAID).
Field of Use
NSAID is used to treat mild to moderate pain and help relieve symptoms of arthritis (e.g., osteoarthritis and rheumatoid arthritis) or gout, such as inflammation, swelling, stiffness, and joint pain.
IPSCIO Record ID: 26558
License Grant
The Mexican Licensee has the Exclusive and non-transferable manufacturing rights and distribution rights in Mexico for Indaflex.
License Property
A Canadian pharma Licensed Indaflex, a lead pharmaceutical product under development for commercialization in Mexico. Licensor owns and/or has rights to the Intellectual Property Rights relating to a pharmaceutical agent for pain control and inflammation treatment;
Indaflex is a topical NSAID formulation intended to be used in the treatment of arthritis. Indaflex is our only prescription drug at the clinical trial stage.
Field of Use
Field of Use relates to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
